ERBB2 and breast carcinoma: Based on that finding, it was proposed that BTK-C signalling could be involved in the appearance of ligand-dependent lapatinib resistance in HER2-positive breast cancer cells and thus may be a potential therapeutic target in combination with HER2 in this subtype of breast carcinoma [29].